Cognitive Impairment and Metabolic Dysfunction in Schizophrenia

Schizophrenia is characterised by pervasive cognitive deficits that span memory, executive function, attention and social cognition. These impairments often emerge before the onset of psychosis and persist throughout the illness, driving functional disability and reducing quality of life. In parallel, metabolic dysfunction—including obesity, dyslipidaemia, insulin resistance and hypertension—occurs at elevated rates in people with schizophrenia. While antipsychotic medications contribute to weight gain and adverse metabolic changes, metabolic abnormalities are also observed in drug-naïve patients, suggesting shared biological pathways. Emerging evidence suggests bidirectional links between cognitive and metabolic health: disrupted glucose and lipid homeostasis may exacerbate neural dysfunction in prefrontal and limbic networks, while chronic cognitive stress and lifestyle factors can worsen metabolic control. Understanding these interconnections offers opportunities for holistic interventions that target both brain and body to improve outcomes.

Research from Nature Portfolio

Recent studies have explored metabolic profiles in first-episode, drug-naïve psychosis patients, revealing early cardiometabolic disturbances that correlate with cognitive and social cognitive deficits. Investigations found that elevated cholesterol and triglyceride levels in newly diagnosed individuals are associated with poorer performance on executive tasks and social cognition measures. These findings indicate that metabolic dysfunction precedes long-term treatment and may contribute to the trajectory of cognitive decline from illness onset.

Cognitive Impairment and Metabolic Dysfunction in Schizophrenia publication trend

The graph below shows the total number of articles in cognitive impairment and metabolic dysfunction in schizophrenia across all publications each year (not limited to Nature Index journals).

Technical terms

Cognitive impairment: A reduction in mental processes such as memory, attention, executive function and social cognition, commonly observed in schizophrenia.

Metabolic syndrome: A cluster of conditions including dyslipidaemia, insulin resistance, obesity and hypertension that increase cardiovascular risk and may exacerbate cognitive deficits.

Functional connectivity: The statistical association between activity in distinct brain regions, often measured by resting-state or task-based functional MRI.

Glycated haemoglobin (HbA1c): A measure of average blood glucose over several months, used to assess long-term glycaemic control.

Apolipoprotein B: A protein component of low-density lipoproteins critical for lipid transport and implicated in neural membrane composition.

Sphingolipid metabolism: A biochemical pathway involving sphingolipids that influences cell membrane structure and signalling, with emerging relevance to cognition and metabolic health.

References

1. Metformin improves cognitive impairment in patients with schizophrenia: associated with enhanced functional connectivity of dorsolateral prefrontal cortex. Translational Psychiatry (2023).
2. Metabolic profile in first episode drug naïve patients with psychosis and its relation to cognitive functions and social cognition: a case control study. Scientific Reports (2023).
3. Metabolic disturbances, hemoglobin A1c, and social cognition impairment in Schizophrenia spectrum disorders. Translational Psychiatry (2022).
4. Association between lipid metabolism and cognitive function in patients with schizophrenia. Frontiers in Psychiatry (2022).